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Abstract 
This manuscript describes the synthesis of a new series of phenyl ethyl thiourea (PET) 
derivatives, with the aim to extend the SAR studies of the well known PET molecules endowed 
with anti-HIV activity. Preliminary results indicated that the synthesized compounds possess low 
anti-HIV activity. 
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Introduction 
 
Human immunodeficiency virus type-1 (HIV-1) is the causative agent for the transmission and 
development of the acquired immunodeficiency syndrome (AIDS).  AIDS remains one of the 
most urgent world health problems, being the leading cause of death in Africa and the fourth 
worldwide.1
Even if there is no definitive cure for HIV infection, a number of drugs slow or halt disease 
progression. However, HIV can rapidly become resistant to any single antiretroviral drug, 
therefore a combination of three or more drugs are usually required to effectively suppress the 
virus. The highly active antiretroviral therapy (HAART)2 consists of the combination of 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) with non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs).2 In this context, while 
NRTIs (e.g. zidovudine, lamivudine, abacavir, tenofovir) act competitively at the catalytic site of 
the RT as DNA chain-terminating analogues of the natural deoxynucleoside triphosphates, 
NNRTIs (e.g. nevirapine, efavirenz) bind to an allosteric site located about 10 Å from the 
catalytic site thus leading to a noncompetitive inhibition of the enzyme.3 The latter ones, despite 
their lower toxicity with respect to NRTIs, are particularly vulnerable to the development of viral 
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resistance caused by mutations in RT that can retain viable enzymatic function. Therefore 
significant efforts in this field have focused on developing new NNRTIs with a favourable 
profile of resilience to many drug resistant mutations.4  
Studies that have been made in the Lilly laboratories on compounds of molecular 
simplification of TIBO (4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-
one) series, evidenced a new lead the N-(2-phenylethyl)-N'-(2-thiazolyl)thiourea named 
LY73497 (Figure 1) which possesses a phenyl ethyl thiourea (PET) motif.5-6 This compound 
showed a significant inhibition value against the RT.  
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Figure 1. Structure of N-(2-phenylethyl)-N'-(2-thiazolyl)thiourea.  
 
Basic SAR studies were performed by notionally dividing LY73497 into four portions and 
independently varying each one of them.5 The results of these SAR studies provided evidence of 
important features for the interaction with RT: i) small electron withdrawing substituents (F, Cl) 
can be favorably introduced on the phenyl ring especially in ortho position; ii)  the ethyl linker is 
optimal for the activity; iii) the urea derivatives are less active than the corresponding thiourea 
derivatives; iv) the thiazolyl nucleus can be replaced successfully with other heterocyclic rings 
such as pyridine, pyrazine, benzothiazole, imidazole, triazole. 
The aim of this work was to synthesize new PET derivatives 1 (Figure 2), in which important 
requirements for the anti-HIV activity such as two aromatic systems, benzene and pyridine, and 
the thiourea moiety were maintained, while the ethylene bridge was modified by introducing a 
carbonyl group and a hydroxyl function. This modification took into account the work of 
Högberg et al.7 in which the introduction of a carbonyl group in proximity of the phenyl ring 
resulted in an enhanced the anti-HIV activity both in enzymatic assays and in cell cultures. The 
importance of this substitution on the ethyl linker was recently confirmed by QSAR studies.8
In compounds of series 1 the introduction of a hydroxyl group on the ethyl linker should 
reduce the conformational freedom by forming an intramolecular hydrogen bond with the sulfur 
atom. Thus, a series of ethers (series 2, Figure 2) were also synthesized to compare them with 
derivatives of series 1 and confirm our hypothesis. On the aromatic ring various halogens atoms 
were introduced, such as chlorine and fluorine, in agreement with the SAR studies on PET 
derivatives. 
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Figure 2. Structure of PET derivatives 1-2. 
 
Results and Discussion 
 
The synthesis of N1-(1-hydroxy-2-oxo-2-phenylethyl)-N3-pyridin-2-yl-thioureas 1a-f was 
realized by nucleophilic addition of 2-pyridylthiourea 5 to the variously substituted 2-oxophenyl-
acetaldehydes 4a-f (Scheme 1), prepared by easy oxidation of the corresponding acetophenones 
3a-f with selenium dioxide according to a previously reported procedure.9 The reaction between 
4a-f and 5 has been promoted by catalytic amounts of the mixture acetic acid/hydrochloric acid 
in dioxane. By maintaining unchanged the reaction conditions and switching the solvent from 
dioxane to ethanol, it was possible to obtain N1-(1-ethoxy-2-oxo-2-phenylethyl)-N3-pyridin-2-yl-
thioureas 2a-f, realistically due to the addition of ethanol to the N-aroylmethylene thiourea 
intermediate. 
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Scheme 1. (a) SeO2, H2O/dioxane, 60°C, 12 h; (b) CH3COOH/HCl, dioxane, reflux, 6-8 h; (c) 
CH3COOH/HCl, ethanol, reflux, 6-8 h.  
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Both series 1a-f and 2a-f have been tested to evaluate their anti-HIV activity at National 
Cancer Institute (NCI) of Bethesda, USA. The assay was carried on MT-4 cell lines exposed to 
the strain HIV-1 III B in the presence of compounds 1a-f and 2a-f to determine the concentration 
that reduces to the 50% (EC50) the cytopathic effect induced by HIV-1 in MT-4 cells, the 
cytotoxicity (CC50) and the selectivity index that is the ratio CC50/EC50.  
Only the derivatives 1a, 1c, 2a and 2c showed a moderate anti-HIV activity (Table 1), with 
an EC50 value of 118.08 µM and 166.25 µM for the hydroxyl derivatives 1a and 1c, and of 67.05 
µM and 69.48 µM for the O-ethyl derivatives 2a and 2c respectively. All the other compounds 
protected the MT-4 cells from the cytopathic effect in a low percentage (8-22%). Generally, all 
compounds showed a very low cytotoxicity profile >400 µM for the derivatives 1a-f  and >200 
µM for O-ethyl analogues 2a-f. 
 
Table 1. Anti-HIV activity (EC50), cytotoxicity (CC50), and selectivity index in MT-4 cells of 
compounds 1 and 2. 
 
NN
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1 2  
Compd. R EC50 (µM)aor protection % CC50 (µM)b SIc
1a 2-Cl 118.08 >400 >3 
1b 3-Cl 13% >400  
1c 4-Cl 166.25 >400 >2 
1d 2-F 8% >400  
1e 4-F 12% >400  
1f 2,6-F 16% >400  
2a 2-Cl 67.05 >200  
2b 3-Cl 15% >200  
2c 4-Cl 69.48 210 3 
2d 2-F 21% >200  
2e 4-F 18% >200  
2f 2,6-F 22% >200  
LY73497 1.35 >3805  
aConcentration that reduces to the 50% the cytopathic effect induced by HIV-1 in MT-4 (for 
details, see Exper. Part).  
bConcentration that reduces to the 50% the growth of the MT-4 cells.  
c Selectivity index: ratio CC50/EC50. 
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The obtained results suggested that the presence of a chlorine atom at position 2 or 4 of the 
phenyl ring positively affected the anti-HIV activity of this new series of PET derivatives. The 
slightly higher activity of O-ethyl derivatives 2a and 2c with respect to the corresponding 
hydroxyl derivatives 1a and 1c indicated that a hydrophobic character of the linker is favourable 
for antiviral activity. This is confirmed when we compare our results either with the LY73497 
analogues or the series of compounds with the carbonyl function next to phenyl ring.5,7  
In conclusion, this work may offer an additional contribution to extend the SAR studies of the 
well known PET derivatives endowed with anti-HIV activity, useful for further developments of 
this series. 
 
 
Experimental Section  
 
General. Melting points were determined on a Kofler hot-stage apparatus and are uncorrected. 
Elemental analyses (C, H, N) were carried out on a Carlo Erba Model 1106 elemental analyzer; 
the results were correct within ±0.4% of the calc. values. Merck silica-gel 60 F254 plates were 
used for anal. TLC, and column chromatography (CC) was performed on Merck silica gel 60 
(70-230 mesh). 1H-NMR Spectra were recorded in CDCl3 on a Varian Gemini-300 spectrometer; 
chemical shifts δ in ppm rel. to Me4Si, coupling constants J in Hz.  
 
General procedure for the synthesis of substituted 2-oxophenyl-acetaldehydes 4 
Selenium dioxide (11 mmol) was solubilized in a mixture water/dioxane (26 mL, 4/96) at 60°C, 
when the solution was homogenous, it was cooled and the required acetophenone 3 (11 mmol) 
was added. The reaction mixture was heated at 100°C for 12 h filtered on celite and then 
evaporated to dryness. The residue was diluted with ethyl acetate, washed with water, then 
saturated NaHCO3 and dried (Na2SO4). The solvent was evaporated and the residue containing 
the title compound in quantitative yields (as observed by TLC) was used for the next step 
without any further purification. 
 
General procedure for the synthesis of N1-[2-aryl-1-hydroxy-2-oxoethyl]-N3-pyridin-2-yl-
thioureas 1a-f 
2-Pyridylthiourea 5 (200 mg, 1.3 mmol), acetic acid (0.6 mL) and hydrochloric acid (0.6 mL) 
were added to a solution of variously substituted 2-oxophenyl-acetaldehydes 4a-f 9 (1.5 mmol) in 
15 mL of dioxane. The reaction mixture was stirred at 100 °C for 8 h, then cooled and 
evaporated to dryness. The residue was purified by column chromatography using silica gel as 
absorbent with 9:1 CHCl3/MeOH as eluent to give the title compounds.  
N1-[2-(2-Chlorophenyl)-1-hydroxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 1a. Yield: 53%. Mp 
157-159 °C. 1H NMR (CDCl3): 6.40 (d, 1H, J = 7.72, CH), 7.04–8.24 (m, 8H, arom. H), 10.86 
(s, 1H, H-N(3)), 12.77 (d, 1H, J = 7.72, H-N(1)). Anal. calc. for C14H12ClN3O2S (321.79): C, 
52.26; H, 3.76; N, 13.06. Found: C, 51.90; H, 4.10; N, 12.76. 
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N1-[2-(3-Chlorophenyl)-1-hydroxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 1b. Yield: 31%. Mp 
dec. > 193 °C 1H NMR (CDCl3): 5.48 (d, 1H, J = 6.20, CH), 7.01–8.28 (m, 8H, arom. H), 10.48 
(s, 1H, H-N(3)), 12.33 (d, 1H, J = 6.20, H-N(1)). Anal. calc. for C14H12ClN3O2S (321.79): C, 
52.26; H, 3.76; N, 13.06. Found: C, 52.21; H, 3.59; N, 13.15. 
N1-[2-(4-Chlorophenyl)-1-hydroxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 1c. Yield: 37%: Mp 
160-162 °C. 1H NMR (CDCl3): 5.94 (d, 1H, J = 7.14, CH), 7.05–8.31 (m, 8H, arom.H), 10.85 (s, 
1H, H-N(3)), 12.50 (d, 1H, J = 7.14, H-N(1)). Anal. calc. for C14H12ClN3O2S (321.79): C, 52.26; 
H, 3.76; N, 13.06. Found: C, 52.60; H, 3.46; N, 13.40. 
N1-[2-(2-Fluorophenyl)-1-hydroxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 1d. Yield: 61%. Mp 
188-191 °C. 1H NMR (CDCl3): 5.80 (d, 1H, J = 6.59, CH), 7.01–8.25 (m, 8H, aromH), 10.47 (s, 
1H, H-N(3)), 12.43 (d, 1H, J = 6.59, H-N(1)). Anal. calc. for C14H12FlN3O2S (305.33): C, 55.07; 
H, 3.96; N, 13.76. Found: C, 54.87; H, 4.16; N, 13.10. 
N1-[2-(4-Fluorophenyl)-1-hydroxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 1e. Yield: 25%. Mp 
152-155 °C. 1H NMR (CDCl3): 5.54 (d, 1H, J = 6.92, CH), 6.99–8.27 (m, 8H, arom.H), 10.44 (s, 
1H, H-N(3)), 12.35 (d, 1H, J = 6.92, H-N(1)). Anal. calc. for C14H12FlN3O2S (305.33): C, 55.07; 
H, 3.96; N, 13.76. Found: C, 54.91; H, 4.27; N, 13.45. 
N1-[2-(2,6-Difluorophenyl)-1-hydroxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 1f. Yield: 27%. 
Mp dec. > 215 °C. 1H NMR (CDCl3): 5.83 (d, 1H, J = 6.71, CH), 6.90–8.19 (m, 7H, arom.H), 
10.37 (s, 1H, H-N(3)), 12.34 (d, 1H, J = 6.71, H-N(1)). Anal. calc. for C14H12FlN3O2S (323.32): 
C, 52.01; H, 3.43; N, 13.00. Found: C, 51.66; H, 3.58; N, 13.36. 
General Procedure for the Synthesis of the N1-[2-aryl-1-ethoxy-2-oxoethyl]-N3-pyridin-2-yl-
thioureas 2a-f. The synthesis of compounds 5a-f was realized in an analogous manner to that 
reported for compounds 4a-f, using ethanol as solvent instead of dioxane. The pure title 
compound was recovered by recrystallisation from ethanol. 
N1-[2-(2-Chlorophenyl)-1-ethoxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 2a. Yield: 27%. Mp 
119-121 °C. 1H NMR (CDCl3): 1.23 (t, 3H, J = 7.2, Me), 4.24 (m, 2H, CH2), 6.57 (d, 1H, J = 
7.69, CH), 6.72–8.25 (m, 8H, arom.H), 8.70 (s, 1H, H-N(3)), 12.93 (d, 1H, J = 7.69, H-N(1)). 
Anal. calc. for C16H16ClN3O2S (349.89): C, 54.93; H, 4.61; N, 12.01. Found: C, 54.73; H, 4.96; 
N, 11.76. 
N1-[2-(3-Chlorophenyl)-1-ethoxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 2b. Yield: 29%. Mp 
128-130 °C. 1H NMR (CDCl3): 1.15 (t, 3H, J = 7.14, Me), 4.15 (m, 2H, CH2), 6.02 (d, 1H, J = 
6.86, CH), 7.07-8.25 (m, 8H, arom.H), 10.93 (s, 1H, H-N(3)), 12.80 (d, 1H, J = 6.86, H-N(1)). 
Anal. calc. for C16H16ClN3O2S (349.89): C, 54.93; H, 4.61; N, 12.01. Found: C, 54.67; H, 4.86; 
N, 12.41. 
N1-[2-(4-Chlorophenyl)-1-ethoxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 2c. Yield: 75%. Mp 
139-142 °C. 1H NMR (CDCl3): 1.25 (t, 3H, J = 6.95, Me), 4.22 (m, 2H, CH2), 5.74 (d, 1H, J = 
6.95, CH), 7.31–8.15 (m, 8H, arom.H), 10.42 (s, 1H, H-N(3)), 14.33 (d, 1H, J = 6.95, H-N(1)). 
Anal. calc. for C16H16ClN3O2S (349.89): C, 54.93; H, 4.61; N, 12.01. Found: C, 54.83; H, 4.44; 
N, 12.38. 
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Synthesis of N1-[2-(2-Fluorophenyl)-1-ethoxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 2d. 
Yield: 26%. Mp 152-153 °C. 1H NMR (CDCl3): 1.23 (t, 3H, J = 6.95, Me), 4.23 (m, 2H, CH2), 
6.42 (d, 1H, J = 7.32, CH), 6.64–8.29 (m, 8H, arom.H), 12.80 (d, 1H, J = 7.32, H-N(1)). Anal. 
calc. for C16H16FN3O2S (333.39): C, 57.64; H, 4.84; N, 12.60. Found: C, 57.94; H, 4.50; N, 
12.20. 
N1-[2-(4-Fluorophenyl)-1-ethoxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 2e. Yield: 88% Mp 
133-135 °C. 1H NMR (CDCl3): 1.25 (t, 3H, J = 7.1, Me), 4.24 (m, 2H, CH2), 6.11 (d, 1H, J = 
7.0, CH), 6.68–8.29 (m, 8H, arom.H), 8.38 (s, 1H, H-N(3)), 12.76 (d, 1H, J = 7.0, H-N(1)). Anal. 
calc. for C16H16FN3O2S (333.39): C, 57.64; H, 4.84; N, 12.60. Found: C, 57.99; H, 4.53; N, 
12.35. 
N1-[2-(2,6-Difluorophenyl)-1-ethoxy-2-oxoethyl]-N3-pyridin-2-yl-thiourea 2f. Yield: 70%. 
Mp 177-180 °C. 1H NMR (CDCl3): 1.25 (t, 3H, J = 7.1, Me), 4.24 (m, 2H, CH2), 6.11 (d, 1H, J = 
7.0, CH), 6.68–8.29 (m, 8H, arom.H), 8.38 (s, 1H, H-N(3)), 12.76 (d, 1H, J = 7.0, H-N(1)). Anal. 
calc. for C16H15F2N3O2S (351.38): C, 54.69; H, 4.30; N, 11.96. Found: C, 54.91; H, 4.62; N, 
11.80. 
 
Pharmacology. The in vitro anti-HIV drug testing system was performed in the National Cancer 
Institute’s Developmental Therapeutics Program, AIDS antiviral screening program, according 
to reported procedures.10 The assay involves the killing of T4 lymphocytes by HIV-1. T4 
lymphocytes (CEM-SS cell line) are exposed to HIV-1 (RF strain) at a multiplicity of infection 
(MOI) of approximately 0.05. Each agent, dissolved in dimethyl sulfoxide, was added at varying 
concentrations ranging from 10-9 to 10-5 M. Uninfected cells with the test compound serve as 
toxicity control, and infected and uninfected cells without the compound serve as basic controls. 
Activity is expressed as the effective concentration 50% (EC50) which represents the 
concentration of each compound resulting in a 50% reduction of the viral cytopathic effect. The 
50% inhibitory concentration (CC50) represents the toxic concentration of drug resulting in 50% 
growth inhibition of normal, uninfected cells. The selectivity index (SI) is determined by 
dividing CC50 by EC50. 
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